ArticleThe Journal of allergy and clinical immunology2008
An age-dependent association of mannose-binding lectin-2 genetic variants on HIV-1-related disease in children.
Article in The Journal of allergy and clinical immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Genomic Factors and Therapeutic Approaches in HIV-Associated Neurocognitive Disorders: A Comprehensive Review.International journal of molecular sciences · 2023Review
- TRIM22 genotype is not associated with markers of disease progression in children with HIV-1 infection.AIDS (London, England) · 2021Article
- Risk Factors and Pathogenesis of HIV-Associated Neurocognitive Disorder: The Role of Host Genetics.International journal of molecular sciences · 2018Review
- Host genetic factors predisposing to HIV-associated neurocognitive disorder.Current HIV/AIDS reports · 2014Review
- Associations of host genetic variants on CD4⁺ lymphocyte count and plasma HIV-1 RNA in antiretroviral naïve children.The Pediatric infectious disease journal · 2014Article
- How does mother-to-child transmission of HIV differ among African populations? Lessons from MBL2 genetic variation in Zimbabweans.Omics : a journal of integrative biology · 2014Article
- Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder.Journal of acquired immune deficiency syndromes (1999) · 2014Review
- Complement and HIV-I infection/HIV-associated neurocognitive disorders.Journal of neurovirology · 2014Review
- Genetic variants in the host restriction factor APOBEC3G are associated with HIV-1-related disease progression and central nervous system impairment in children.Journal of acquired immune deficiency syndromes (1999) · 2013Article
- Mannose-binding lectin binds to amyloid β protein and modulates inflammation.Journal of biomedicine & biotechnology · 2012Article
- Mannose-binding lectin and the balance between immune protection and complication.Expert review of anti-infective therapy · 2011Review
- Mannose binding lectin mediated complement pathway in multiple sclerosis.Journal of neuroimmunology · 2011Article
- Expression of mannose binding lectin in HIV-1-infected brain: implications for HIV-related neuronal damage and neuroAIDS.Neurobehavioral HIV medicine · 2011Article
- Infections of people with complement deficiencies and patients who have undergone splenectomy.Clinical microbiology reviews · 2010Review
- The good and evil of complement activation in HIV-1 infection.Cellular & molecular immunology · 2010Review
- Genetic testing and HIV dementia: teasing out the molecular mechanisms of disease.AIDS (London, England) · 2010Article
- APOE epsilon4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors.AIDS (London, England) · 2010Article
- Host genetic determinants of human immunodeficiency virus infection and disease progression in children.Pediatric research · 2009Review
- Advances in basic and clinical immunology in 2008.The Journal of allergy and clinical immunology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundMannose-binding lectin (MBL) is part of the lectin pathway of complement activation against various pathogens; however, its role in innate immune responses against HIV-1 infection in children is unknown.
objectiveThis study evaluated the effects of mannose-binding lectin-2 (MBL2) alleles on HIV-1 disease progression and central nervous system (CNS) impairment in children.
methodsA cohort of 1037 HIV-1-infected children enrolled in Pediatrics AIDS Clinical Trial Group protocols P152 and P300 before the availability of effective antiretroviral therapy was genotyped for MBL2 and evaluated for disease progression.
resultsChildren with the homozygous variant MBL2-O/O genotype were more likely to experience rapid disease progression and CNS impairment than those with the wild-type AA genotype. The effects were predominantly observed in children younger than 2 years. In unadjusted Cox proportional hazards models, children younger than 2 years with MBL2-O/O experienced more rapid disease progression (O/O vs AA: relative hazard [RH], 1.54; 95% CI, 1.07-2.22; P = .02; O/O vs A/O: RH, 2.28; 95% CI, 1.09-4.79; P = .029). Similarly, children with MBL2-O/O were more likely to experience rapid progression to CNS impairment (O/O vs A/A: RH, 2.78; 95% CI, 1.06-2.69, P = .027; O/O vs A/O: RH, 1.69; 95% CI, 1.07-7.21; P = .035). The effects remained significant after adjustment for CD4(+) lymphocyte count, plasma HIV-1 RNA, and other genotypes.
conclusionsMBL2-O/O genotypes, which result in lower expression of MBL, are associated with more rapid HIV-1-related disease progression, including CNS impairment, predominantly in children younger than 2 years. These data suggest that MBL2 variants are associated with altered HIV-1 disease progression, particularly in young children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.